Company updateEconomic Times
Biocon gets USFDA nod for breast cancer biosimilar Pebrilzo
Positive+384 sources
GreyOak summary
Biocon Ltd received USFDA approval for Pebrilzo, a biosimilar to Perjeta for HER2-positive breast cancer. This marks the fifth oncology biosimilar therapy approved in the US for the company.
What it affects
- BioconBIOCONPositive +38
Received USFDA nod for breast cancer biosimilar Pebrilzo.Rolling sentiment Positive +21
Source
Read the original at Economic TimesMore Biocon news
No other recent stories about Biocon.
All Biocon news →